Amendments To The Claims

The listing of claims will replace all prior versions, and listings, of the claims in the application.

Listing Of Claims:

Claims 1-14 (Cancelled)

Claim 15 (Currently Amended) A method for treating type 2 diabetes, said method comprising administering to a patient in need of said treatment i) an effective amount of metformin via oral administration and ii) an effective amount of an insulinotropic GLP-1 related peptide via injection or infusion, where said insulinotropic GLP-1 related peptide is GLP-1 (7-37), GLP-1 (7-36) amide, or an analogue of GLP-1 (7-37) or GLP-1 (7-36) amide [, or a functional derivative thereof].

Claim 16 (Currently Amended) The method of claim 15, wherein said insulinotropic GLP-1 related peptide is GLP-1 (7-36) amide.

Claim 17 (Currently Amended) The method of claim 15, wherein said insulinotropic GLP-1 related peptide is an analogue of GLP-1 (7-37).

Claim 18 (Previously presented) The method of claim 17, wherein said analogue of GLP-1 (7-37) has one amino acid of GLP-1 (7-37) exchanged by another amino acid.

Claim 19 (Currently Amended) The method of claim [15] 21, wherein said insulinotropic GLP-1 related peptide is a functional derivative of an analogue of GLP-1 (7-37).

Claim 20 (Amended) The method of claim 19, wherein said analogue of GLP-1 (7-37) has one amino acid of GLP-1(7-37) exchanged by another amino acid.

Claim 21 (New) A method for treating type 2 diabetes, said method comprising administering to a patient in need of said treatment i) an effective amount of metformin via oral administration and ii) an effective amount of an insulinotropic GLP-1 related peptide via injection or infusion, where said insulinotropic GLP-1 related peptide is a functional derivative of GLP-1 (7-37), GLP-1 (7-36) amide, or a functional derivative of an analogue of GLP-1 (7-37) or GLP-1 (7-36) amide.

Claim 22 (New) A method for treating type 2 diabetes, said method comprising administering to a patient in need of said treatment an amount of metformin and an amount of an insulinotropic peptide effective to treat said type 2 diabetes.

Claim 23 (New) The method of claim 22, wherein the insulinotropic peptide is an insulinotropic GLP-1 related peptide selected from the group consisting of GLP-1 (7-37), GLP-1 (7-36) amide, or an analogue of GLP-1 (7-37) or GLP-1 (7-36) amide.

Claim 24 (New) The method of claim 22, wherein the insulinotropic peptide is an insulinotropic GLP-1 related peptide selected from the group consisting of a functional derivative of GLP-1 (7-37), GLP-1 (7-36) amide, or a functional derivative of an analogue of GLP-1 (7-37) or GLP-1 (7-36) amide.

Claim 25 (New) The method of claim 23, wherein said insulinotropic GLP-1 related peptide is GLP-1 (7-36) amide.

Claim 26 (New) The method of claim 23, wherein said insulinotropic GLP-1 related peptide is an analogue of GLP-1 (7-37).

Claim 27 (New) The method of claim 26, wherein said analogue of GLP-1 (7-37) has one amino acid of GLP-1 (7-37) exchanged by another amino acid.

Claim 28 (New) The method of claim 24, wherein said insulinotropic GLP-1 related peptide is a functional derivative of an analogue of GLP-1 (7-37).

Claim 29 (New) The method of claim 28, wherein said analogue of GLP-1 (7-37) has one amino acid of GLP-1(7-37) exchanged by another amino acid.

Claim 30 (New) The method of claim 22, wherein the insulinotropic peptide is administered to the subject via injection or infusion.

Claim 31 (New) The method of claim 22, wherein the metformin is administered to the subject orally.

Claim 32 (New) The method of claim 22, wherein said metformin is administered to the subject orally and said insulinotropic peptide is administered to the subject via injection or infusion.